From the Hellstrom paradox toward cancer cure
| Autor: | Karl Erik Hellstrom, Ingegerd Hellström |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
business.industry medicine.drug_class medicine.medical_treatment Immune checkpoint inhibitors Cancer therapy Cancer Immunosuppression Immunotherapy medicine.disease Monoclonal antibody medicine.disease_cause Autoimmunity 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Tumor rejection Cancer research Medicine business |
| DOI: | 10.1016/bs.pmbts.2018.11.002 |
| Popis: | Several decades ago we published some of the first papers showing that both murine and human cancers are recognized in vitro as immunologically foreign and that this is the case also in the presence of a growing tumor. The latter situation, sometimes referred to as the Hellstrom paradox, implies that the tumor is protected in vivo by a highly immunosuppressive environment. After many disappointments, the discovery that tumor-related immunosuppression can be counteracted by administrating monoclonal antibodies (mAbs) to checkpoint inhibitors such as CTLA-4, PD-1, and PD-L1 is now revolutionizing cancer therapy. Over the past several years we have applied mouse models in attempts to further improve the ability of such mAbs to cause long-term complete tumor rejection. This review is focused on that work and emphasizes that successful immunotherapy is associated with a shift from a tumor-promoting Th2 inflammation to a tumor-inhibiting Th1 response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|